By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Myriad Genetics, Inc. 

320 Wakara Way

Salt Lake City  Utah  84108  U.S.A.
Phone: 801-584-3600 Fax: 801-584-3640


SEARCH JOBS

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.

YEAR FOUNDED:

May 1991

LEADERSHIP:

CEO and Founder: Mark Capone

CMO (Medical): Richard Wenstrup

CFO: Bryan Riggsbee

CSO (Scientific): Jerry Lanchbury

JOBS:

Please click here for Myriad Genetics job opportunities.

CLINICAL TRIAL

Please click here for clinical trial information.


PRODUCTS:

All Products

FOLLOW MYRIAD GENETICS:



Key Statistics


Email: info@myriad.com
Ownership: Public

Web Site: Myriad Genetics
Employees:
Symbol: MYGN
 









Company News
Myriad Genetics (MYGN) To Present Seven Studies At The 2017 ASCO Annual Meeting 5/18/2017 12:29:22 PM
Myriad Genetics (MYGN)’ Prolaris Test Accurately Predicts The 10-Year Risk Of Metastases In Men Treated For Prostate Cancer 5/12/2017 7:51:41 AM
Myriad Genetics (MYGN) To Present Results From Four Studies At American Urological Association 2017 Annual Meeting 5/5/2017 10:38:24 AM
Myriad Genetics (MYGN) Reports Fiscal Third-Quarter 2017 Financial Results 5/3/2017 8:10:56 AM
Myriad Genetics (MYGN) And Clovis Oncology (CLVS) Sign Agreement For Use Of FDA-Approved Bracanalysis Cdx® Test To Identify Patients With Germline BRCA Mutations For Rubraca (Rucaparib) Treatment 4/27/2017 8:18:40 AM
Myriad Genetics (MYGN) To Announce Fiscal Third-Quarter 2017 Financial Results On May 2, 2017 4/19/2017 8:15:21 AM
BeiGene (BGNE) And Myriad Genetics (MYGN) Collaborate On Diagnostic For PARP Inhibitor 4/17/2017 10:41:05 AM
Study Finds Wide Gap In Quality Of BRCA1/2 Variant Classification Between Myriad Genetics (MYGN) And A Common Public Database 4/17/2017 7:58:43 AM
Myriad Genetics (MYGN) And BeiGene (BGNE) Sign Agreement To Develop Companion Diagnostics For Use With Beigene’s Novel PARP Inhibitor, BGB-290 4/6/2017 11:16:22 AM
Pivotal Study Results For Myriad Genetics (MYGN)’s myPATH Melanoma Test Highlighted In Two Additional Scientific Publications 4/5/2017 11:11:53 AM
12345678910...
//-->